Journal article
Cerebral cortical thickness after treatment with desvenlafaxine succinate in major depressive disorder
Abstract
Thickness of the cerebral cortex has been previously investigated for its potential as a biomarker in major depressive disorder (MDD). This is the first study to examine the longitudinal effects of a serotonin-norepinephrine reuptake inhibitor, desvenlafaxine succinate (DVS), on whole-brain cortical thickness (CT) in patients treated for MDD. We also aimed to replicate a previous finding of an association between improvement in clinical …
Authors
Suh JS; Minuzzi L; Cudney LE; Maich W; Eltayebani M; Soares CN; Frey BN
Journal
Neuroreport, Vol. 30, No. 5, pp. 378–382
Publisher
Wolters Kluwer
Publication Date
March 20, 2019
DOI
10.1097/wnr.0000000000001211
ISSN
0959-4965